Sign In

Login

Password

Forgot Password ? Sign Up

Conjugué anticorps-médicament (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Conjugué anticorps-médicament" in French language version.

refsWebsite
Global rank French rank
8doi.org
2nd place
3rd place
7issn.org
57th place
4th place
4nih.gov
4th place
12th place
3adcreview.com
low place
low place
2nature.com
234th place
147th place
1bnnbloomberg.ca
low place
low place
1genengnews.com
low place
low place
1tandfonline.com
507th place
420th place
1mdpi.com
2,912th place
1,010th place
1web.archive.org
1st place
1st place
1fda.gov
447th place
1,409th place
1gene.com
low place
low place
1cancer.gov
1,684th place
6,412th place
1clinicaltrials.gov
5,225th place
6,624th place
1sante.fr
8,603rd place
517th place
1japantimes.co.jp
389th place
616th place

adcreview.com

  • Brentuximab vedotin (SGN35), ADC Review/Journal of Antibody-drug Conjugates
  • Inotuzumab ozogamicin (drug description), ADC Review/Journal of Antibody-drug Conjugates [3]
  • U.S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R B-cell precursor Acute Lymphoblastic Leukemia, ADC Review/Journal of Antibody-drug Conjugates, August 17, 2017 [4]

bnnbloomberg.ca

cancer.gov

  • Ado-trastuzumab emtansine (U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute.) [2]

clinicaltrials.gov

doi.org

dx.doi.org

doi.org

fda.gov

gene.com

  • FDA Approves Genentech's Kadcyla® (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer [1]

genengnews.com

issn.org

portal.issn.org

japantimes.co.jp

  • (en-US) Kanoko Matsuyama, « Drug devised to replace chemotherapy may reshape cancer care », The Japan Times Online,‎ (ISSN 0447-5763, lire en ligne, consulté le )

mdpi.com

nature.com

  • (en) Alexander H. Staudacher et Michael P. Brown, « Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? », British Journal of Cancer, vol. 117, no 12,‎ , p. 1736–1742 (ISSN 1532-1827, DOI 10.1038/bjc.2017.367, lire en ligne, consulté le )
  • (en) Zhiwen Fu, Shijun Li, Sifei Han et Chen Shi, « Antibody drug conjugate: the “biological missile” for targeted cancer therapy », Signal Transduction and Targeted Therapy, vol. 7, no 1,‎ , p. 1–25 (ISSN 2059-3635, PMID 35318309, PMCID PMC8941077, DOI 10.1038/s41392-022-00947-7, lire en ligne, consulté le )

nih.gov

ncbi.nlm.nih.gov

  • Ravi V. J. Chari, Bridget A. Martell, Jonathan L. Gross, Sherrilyn B. Cook, Sudhir A. Shah, Walter A. Blättler, Sara J. McKenzie et Victor S. Goldmacher, « Immunoconjugates containing novel maytansinoids: promising anticancer drugs », Cancer Research, vol. 52, no 1,‎ , p. 127–31 (PMID 1727373)
  • Yu-Tzu Tai, Patrick A. Mayes, Chirag Acharya et Mike Y. Zhong, « Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma », Blood, vol. 123, no 20,‎ , p. 3128–3138 (ISSN 0006-4971 et 1528-0020, PMID 24569262, PMCID PMC4023420, DOI 10.1182/blood-2013-10-535088, lire en ligne, consulté le )
  • (en) Jakub Radocha, Niels W. C. J. van de Donk et Katja Weisel, « Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma », Cancers, vol. 13, no 7,‎ , p. 1571 (ISSN 2072-6694, PMID 33805481, PMCID PMC8037134, DOI 10.3390/cancers13071571, lire en ligne, consulté le )
  • (en) Zhiwen Fu, Shijun Li, Sifei Han et Chen Shi, « Antibody drug conjugate: the “biological missile” for targeted cancer therapy », Signal Transduction and Targeted Therapy, vol. 7, no 1,‎ , p. 1–25 (ISSN 2059-3635, PMID 35318309, PMCID PMC8941077, DOI 10.1038/s41392-022-00947-7, lire en ligne, consulté le )

sante.fr

ansm.sante.fr

tandfonline.com

web.archive.org